Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.52 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9341900 | 0.87 | NPC1 (0.54) | NPC1HPGDRAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL8356708 | 0.87 | NPC1 (0.64) | NPC1HPGDRAB9ASMN1; SMN2EGFR | |
| SCHEMBL5457607 | 0.86 | MRGPRX4 (0.54) | NPC1HPGDRAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL229472 | 0.85 | MRGPRX4 (0.69) | HPGDRAB9AMRGPRX4PTGER1S1PR5 | |
| SCHEMBL6808366 | 0.85 | EGFR (0.53) | NPC1HPGDRAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL10604837 | 0.84 | EGFR (0.65) | NPC1HPGDRAB9ASMN1; SMN2EGFR | |
| SCHEMBL4295650 | 0.84 | FOLH1 (0.62) | NPC1HPGDRAB9ASMN1; SMN2PTGER1 | |
| SCHEMBL28979208 | 0.83 | NPC1 (0.53) | NPC1HPGDRAB9ASMN1; SMN2EGFR | |
| SCHEMBL1437989 | 0.83 | FFAR4 (0.58) | NPC1HPGDRAB9ASMN1; SMN2MRGPRX4 | |
| SCHEMBL5468617 | 0.83 | MRGPRX4 (0.57) | NPC1HPGDRAB9ASMN1; SMN2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105309-A1 | Medicinal Compounds | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-7442839-B2 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2008-10-28 | — | — | US | disclosed |
| EP-1675823-B1 | PHENETHANOLAMINE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7402598-B2 | Arylethanolamine β2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2008-07-22 | — | — | US | disclosed |
| EP-1556342-B1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LTD (GB) | 2008-03-26 | — | — | EP | disclosed |
| EP-1554264-B1 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2007-08-08 | — | — | EP | disclosed |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | US | disclosed |
| EP-1675823-A1 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-07-05 | — | — | EP | disclosed |
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | GLAXO GROUP LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
| EP-1556342-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-07-27 | — | — | EP | disclosed |
| EP-1554264-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005040103-A1 | MEDICINAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-05-06 | — | — | WO | disclosed |
| EP-1525180-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004037807-A9 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LTD (GB) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004037807-A2 | MEDICINAL ARYLETHANOLAMINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037773-A1 | PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004016578-A2 | ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
| US-4908386-A | Pharmaceuticals | GLAXO GROUP LIMITED (GB) | 1990-03-13 | — | — | US | disclosed |
| EP-0220054-A2 | Ethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111344-A1 | Arylethanolamine beta2-adrenoreceptor agonist compounds | ADRB2, ADRB1, ADRA2A | NPC1 953/4885HPGD 1207/4885RAB9A 3136/4885 |
| US-20060205794-A1 | Phenethanolamine derivative for the treatment of respiratory diseases | PHOSPHO1, PNMT, NAPEPLD | NPC1 1249/4885HPGD 337/4885RAB9A 1770/4885 |
| US-20060205790-A1 | Medicinal arylethanolamine compounds | NAT1, AADAC, AHR | NPC1 292/4885HPGD 400/4885RAB9A 1985/4885 |
| US-20090105309-A1 | Medicinal Compounds | ADRB2, ADRB1, ADRB3 | NPC1 875/4885HPGD 114/4885RAB9A 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.